Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2025)
Historic Research & Development for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $121.1 million.
- Recursion Pharmaceuticals' Research & Development rose 6228.15% to $121.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.7 million, marking a year-over-year increase of 6726.76%. This contributed to the annual value of $314.4 million for FY2024, which is 3034.29% up from last year.
- According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Research & Development is $121.1 million, which was up 6228.15% from $128.6 million recorded in Q2 2025.
- Recursion Pharmaceuticals' Research & Development's 5-year high stood at $129.6 million during Q1 2025, with a 5-year trough of $24.1 million in Q1 2021.
- For the 5-year period, Recursion Pharmaceuticals' Research & Development averaged around $64.5 million, with its median value being $55.1 million (2023).
- In the last 5 years, Recursion Pharmaceuticals' Research & Development soared by 13331.72% in 2021 and then plummeted by 892.9% in 2022.
- Recursion Pharmaceuticals' Research & Development (Quarter) stood at $48.3 million in 2021, then fell by 8.93% to $44.0 million in 2022, then surged by 57.99% to $69.5 million in 2023, then skyrocketed by 41.52% to $98.3 million in 2024, then increased by 23.11% to $121.1 million in 2025.
- Its Research & Development was $121.1 million in Q3 2025, compared to $128.6 million in Q2 2025 and $129.6 million in Q1 2025.